drugset / Trial / NCT00990314

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00990314

Phase 2 Completed 31 enrolled Lung Biotechnology PBC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.

Timeline

Start
2009-11-30
Primary completion
2013-11-30
Completion
2013-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Beraprost Small molecule 60 ug